局部进展期高危因素直肠癌全程新辅助治疗(CAPOX联合放疗)的2期试验
这项2期试验评估全程新辅助治疗(TNT)在高危因素局部进展期直肠癌患者中的安全性和疗效。50例入组、47例可评估,17例(36%)达到病理完全缓解或临床完全缓解,最常见≥3级不良事件为白细胞减少(10.6%)和放射性皮炎(6.4%)。作者认为TNT有效且安全,但长期疗效需进一步评估。
要点
- 47例可评估患者中17例(36%)达到病理完全缓解或临床完全缓解。
- 3例临床完全缓解患者(6.4%)拒绝手术并选择观察等待策略。
- 最常见≥3级不良事件为白细胞减少(10.6%)和放射性皮炎(6.4%)。
核心结论
- 作者认为,全程新辅助治疗在高危因素局部进展期直肠癌患者中有效且安全。
- 作者指出,全程新辅助治疗的长期疗效需要进一步评估。
研究设计与样本
- 这是一项2期试验,纳入诊断为II-III期直肠癌且至少具有一项高危因素的患者。
- 治疗方案为3周期诱导CAPOX化疗,随后盆腔放疗50.4 Gy/28次并同步2周期CAPOX化疗,放疗后再行3周期巩固CAPOX化疗。
- 主要终点为病理完全缓解和R0切除。
- 共50例患者入组,47例可评估。
- 试验在中国临床试验注册中心注册,注册号为ChiCTR-OIN-17012284。
主要发现
- 34例患者(72.3%)完成6至8周期化疗,46例患者(98%)完成计划放疗。
- 17例患者(36%)达到病理完全缓解或临床完全缓解(cCR)。
- 3例cCR患者(6.4%)拒绝手术并选择观察等待策略。
- 最常见的≥3级不良事件为白细胞减少(10.6%)和放射性皮炎(6.4%)。
- 主要手术并发症包括盆腔脓肿/感染2例(4.3%)、吻合口漏和出血各1例(2.2%),均经保守处理。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出,全程新辅助治疗的长期疗效需要进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To evaluate the safety and efficacy of Total neoadjuvant treatment (TNT) in patients with rectal cancer with high risk factors. METHODS AND MATERIALS: We did this phase 2 trial in patients who were diagnosed with stage II-III rectal cancer with at least one of the high risk factors. Three cycles of induction CAPOX were followed by pelvic radiotherapy of 50.4 Gy/28 fractions and two cycles of concurrent CAPOX. Three cycles of consolidation CAPOX were delivered after radiotherapy. Primary endpoints were pathological complete response (pCR) and R0 resection. RESULTS: Fifty patients were enrolled and 47 patients were evaluable. A total of 34 patients (72.3%) completed 6 to 8 cycles of chemotherapy and 46 patients (98%) completed the planned radiotherapy. 17 patients (36%) achieved a pCR or clinical complete response (cCR). Three cCR patients (6.4%) refused the operation and selected a watch-and-wait approach. The most common grade 3 or worse adverse events were leucopenia (10.6%) and radiation dermatitis (6.4%). The major surgical complications included pelvic abscesses/infection in 2 patients (4.3%), anastomotic leakage and hemorrhage in1 patient (2.2%), respectively, which were all addressed with conservative management. CONCLUSIONS: TNT is effective and safe in patients with locally advanced rectal cancer with high risk factors. Long-term efficacies of TNT need to be further evaluated. This trial is registered with Chinese Clinical Trial Registry, number ChiCTR-OIN-17012284.
引用
- Wang X, Yu Y, Meng W, et al. Total neoadjuvant treatment (CAPOX plus radiotherapy) for patients with locally advanced rectal cancer with high risk factors: A phase 2 trial. Radiother Oncol. 2018. PMID: 30381141. doi:10.1016/j.radonc.2018.08.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。